Asia Pacific Prostate Cancer Nuclear Medicine Market Forecast to 2028

Report Code : BMIRE00025670 | Region : Asia Pacific | Industry : Pharmaceuticals | Published Date : 10/Aug/2022
Asia Pacific Prostate Cancer Nuclear Medicine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)

The Asia Pacific prostate cancer nuclear medicine market is expected to grow from US$ 156.10 million in 2022 to US$ 295.37 million by 2028; it is estimated to grow at a CAGR of 11.2% from 2022 to 2028.

Nuclear medicine is mostly used to diagnose cardiovascular disease and cancer. Since the nuclear medicine industry is saturated, many companies and stakeholders are focusing on extending radiopharmaceutical uses in general. The demand and uptake of radiopharmaceuticals are projected to rise as their application areas grow, which would help businesses broaden their product lines and market share in neurological applications in the coming years. PET is a noninvasive nuclear imaging method for cancer diagnosis, staging, and treatment monitoring. PET imaging is done by injecting a positron-tagged radiopharmaceutical into a patient, usually intravenously. Precise imaging may aid physicians in providing better treatment in the era of individualized cancer treatments. The use of modern imaging is growing as it helps get accurate local staging and early metastatic cancer discovery, accurate oligometastatic disease identification, and optimal therapy response assessment. Next-generation imaging modalities, such as whole-body MRI and molecular imaging with combined PET and CT and PET and MRI combination employing innovative radiopharmaceuticals, provide new imaging options for patients with advanced prostate cancer.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC prostate cancer nuclear medicine market. The APAC prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.

APAC Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million )

APAC Prostate cancer nuclear medicine Market Segmentation

The APAC prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the APAC prostate cancer nuclear medicine market is segmented into PET and SPECT. The PET dominated the APAC prostate cancer nuclear medicine market in 2022. Based on PET product, the APAC prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on end user, the APAC prostate cancer nuclear medicine market is segmented into hospitals, clinics, and others. The hospitals segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on country, the APAC prostate cancer nuclear medicine market is segmented into China, Japan, India, South Korea, Australia, and the Rest of APAC. The China segment dominated the APAC prostate cancer nuclear medicine market in 2022.

ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the APAC prostate cancer nuclear medicine market.

The List of Companies - Asia Pacific Prostate Cancer Nuclear Medicine Market

● ImaginAb

● Curium

● Jubilant Radiopharma

● ABX advanced biochemical compounds GmbH

● Telix Pharmaceuticals Ltd

● Novartis AG

● Lantheus Medical Imaging, Inc.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By Type

1.3.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product

1.3.3 APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By End User

1.3.4 APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. APAC Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 APAC PEST Analysis

4.3 Experts Opinion

5. APAC Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Developing Prevalence of Prostate Cancer

5.1.2 Growing Demand for Early and Precise Diagnosis of Prostate Cancer

5.2 Market Restraints

5.2.1 High Price Related to the Prostate Cancer Diagnostics and Treatment

5.3 Market Opportunities

5.3.1 Increasing Use of Radiopharmaceuticals in Prostate Cancer

5.4 Future Trends

5.4.1 Growing Research Activities for Development of Innovative Imaging Agents

5.5 Impact Analysis

6. Prostate Cancer Nuclear Medicine Diagnostics Market– APAC Analysis

6.1 APAC Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis

7. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type

7.1 Overview

7.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)

7.3 SPECT

7.3.1 Overview

7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

7.4 PET

7.4.1 Overview

7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

8. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product

8.1 Overview

8.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)

8.3 F-18

8.3.1 Overview

8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.4 C-11

8.4.1 Overview

8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.5 GA 68 PSMA

8.5.1 Overview

8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9. APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By End User

9.1 Overview

9.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.4 Clinics

9.4.1 Overview

9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

10. APAC Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis

10.1 APAC: Prostate Cancer Nuclear Medicine Diagnostics Market

10.1.1 Overview

10.1.2 APAC: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)

10.1.2.1 China: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.1.1 Overview

10.1.2.1.2 China: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.1.3 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.1.4 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.1.5 China: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.1.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.2.1 Overview

10.1.2.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.2.3 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.2.4 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.2.5 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.1.2.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.3.1 Overview

10.1.2.3.2 India: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.3.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.3.4 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.3.5 India: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.1.2.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.4.1 Overview

10.1.2.4.2 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.4.3 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.4.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.4.5 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.1.2.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.5.1 Overview

10.1.2.5.2 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.5.3 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.5.4 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.5.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.1.2.6 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.6.1 Overview

10.1.2.6.2 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.2.6.3 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.1.2.6.4 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.1.2.6.5 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

11. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 ImaginAb

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Curium

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Jubilant Radiopharma

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 ABX advanced biochemical compounds GmbH

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Telix Pharmaceuticals Ltd.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Novartis AG

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Lantheus Medical Imaging, Inc.

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1.             China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 2.             China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 3.             China Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 4.             Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 5.             Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028  (US$ Million)

Table 6.             Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 7.             India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type– Revenue and Forecast to 2028 (US$ Million)

Table 8.             India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 9.             India Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 10.          Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Australia Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 13.          South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 14.          South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 15.          South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 16.          Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Rest of Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 19.          Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 20.          Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 21.          Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market

The List of Companies - Asia Pacific Prostate Cancer Nuclear Medicine Market

● ImaginAb

● Curium

● Jubilant Radiopharma

● ABX advanced biochemical compounds GmbH

● Telix Pharmaceuticals Ltd

● Novartis AG

● Lantheus Medical Imaging, Inc.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC prostate cancer nuclear medicine market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the APAC prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the APAC prostate cancer nuclear medicine market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Asia Pacific Prostate Cancer Nuclear Medicine Market Forecast to 2028 )
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry